Monopar Therapeutics (NASDAQ:MNPR) Sees Strong Trading Volume – Still a Buy?

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) saw unusually-high trading volume on Tuesday . Approximately 115,432 shares traded hands during trading, an increase of 99% from the previous session’s volume of 57,974 shares.The stock last traded at $79.9850 and had previously closed at $83.06.

Analysts Set New Price Targets

Several brokerages have commented on MNPR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Wednesday, October 8th. Lake Street Capital started coverage on shares of Monopar Therapeutics in a research note on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 target price on the stock. Oppenheimer set a $115.00 target price on shares of Monopar Therapeutics and gave the stock an “outperform” rating in a report on Thursday, October 2nd. BTIG Research boosted their target price on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, Piper Sandler set a $95.00 price target on Monopar Therapeutics and gave the company an “overweight” rating in a research report on Thursday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $106.20.

Monopar Therapeutics Stock Performance

The firm’s 50-day simple moving average is $85.23 and its 200-day simple moving average is $55.68. The company has a market capitalization of $530.86 million, a price-to-earnings ratio of -23.10 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). Equities research analysts forecast that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Insider Activity at Monopar Therapeutics

In other news, major shareholder Tactic Pharma Llc sold 550,229 shares of Monopar Therapeutics stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total transaction of $35,000,066.69. Following the sale, the insider owned 272,026 shares of the company’s stock, valued at approximately $17,303,573.86. This trade represents a 66.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MNPR. Russell Investments Group Ltd. bought a new stake in Monopar Therapeutics in the 3rd quarter valued at $28,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at about $34,000. AlphaQuest LLC bought a new stake in Monopar Therapeutics in the first quarter valued at about $44,000. BNP Paribas Financial Markets raised its position in Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.